Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
9 hedge funds and large institutions have $46.1M invested in Verona Pharma in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.77% more ownership
Funds ownership: 0% → 3.77% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$9.81M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$9.33M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$8.83M |
| 4 |
O
OrbiMed
New York
|
+$8.83M |
| 5 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$8.13M |
Top Sellers
VRNA Hedge Fund Activity: Q2 2017 in Review
9 of the 4,006 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2017, worth a combined $46.1M.
Buyers outnumbered sellers: 9 funds opened new VRNA positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $9.81M.
- 9 institutional investors held Verona Pharma (VRNA) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $46.1M of Verona Pharma stock for Q2 2017.
- 9 funds opened new Verona Pharma positions in Q2 2017 and 0 closed out, a net change of +9 holders.
- The largest Verona Pharma buyer in Q2 2017 was Novo Holdings A/S, an estimated $9.81M added.
Based on aggregated 13F filings for Q2 2017.